Biopta
ビオプタ別名
銘柄コード
—
上場市場
—
国
従業員（単独）
—
関連会社
4
§01
基本情報
- 所在地
- 未記載
- 社長
- 未記載
- 従業員数(単独)
- 従業員数(連結)
- 開始日
- 2003-02-01
- 終了日
§02
サイト
§03
事業内容
GMP-grade iMSC & MSC productionStem Cell ReagentsCellsStem Cell Products3D Cell CultureLabwareClinical-grade stem cell servicesGene editing servicesGenomic & bioinformatics servicesGMP iPSC & iMSC MCB manufacturingGMP manufacturing facilityiPSC-derived exosome production serviceRegenerative medicine productsCustom research stem cell servicesDonor recruitmentCustom reprogrammingExpansion & characterizationGenomic servicesNucleic acid extractionReal-time PCRBiomarker discovery and validationNext-Generation SequencingOligonucleotide Synthesis ServiceNeoantigen Detection ServiceCellular ServicesCentral Lab ServicesBiomarker ServicesMolecular ServicesProject ManagementCells and products for stem cell research and 3D cell cultureRNA ReprogrammingSmall MoleculesGene Editing ProductsStemfactor Growth Factors and CytokinesQkine Growth Factors and CytokinesAntibodies and Staining KitsStem Cell Culture MediaCell SubstratesCryopreservation MediaDissociation SolutionsTransfection ReagentsStemRNA Induced Pluripotent Stem Cells (iPSCs)StemEdit Gene Edited iPSCsDifferentiated iPSCs and Related ReagentsMesenchymal Stem Cells (MSCs)Immortalized Cell Lines and Related ReagentsFeeder CellsiPSC-derived ExosomesAlvetex 3D Cell Culture SystemsAlvetex Advanced Tissue Bioengineering SystemEZSPHERE Multiwell Dishes and PlatesKOKEN Atelocollagen (AteloCell)ABLE Biott Bioreactor SystemsBioThrust Bioreactor Systems2mag Stirring SystemsDistributors of REPROCELL Products Worldwidecontract research services in human /drug-efficacy-safety-admeex vivo living tissues /drug-efficacy-safety-admeclinical trials for neurodegenerative disease treatmentsdiagnostic services and clinical research servicesDevelopment and commercialization of culture media for human ES/iPS cellsProduction of cardiomyocytes derived from human iPS cellsProduction of neurons derived from human iPS cellsStem cell-based drug development support technologiesResearch and development in regenerative medicine and tailor-made medicineUse of human fresh tissues3D modelsUse of iPSCs to characterize drug efficacy and inter-patient variabilityPredictive drug discovery servicesBioengineered tissue model servicesStem cell research productsiPSC-derived human cardiomyocytes, hepatocytes, and neuronal cells3D cell culture and bioengineered tissuesdrug discoveryclinical MSC and MSC-derived ATMPs CDMO servicesNIPT clinical servicesPCR testing services for COVID-19personal iPS servicecGMP suite for iPSC-derived glial progenitorsCRISPR/Cas9 genome editing servicesLaboratory services for drug discoveryBiomarker and genetic discovery collaborationStem cell therapy technologyDevelopment and sale of human iPSC-derived cell modelsCustom-made disease model cellsCell therapy development servicesStem cell research servicesDiagnostic development servicesPreclinical drug development servicesClinical drug development servicesStem cell reagentsStem cell products3D cell culture products
§04
関連会社
| 会社名 | Group | 親会社 | 子会社 | 得意先 | 仕入先 | 業務提携 | 銀行等 | 株主等 |
|---|---|---|---|---|---|---|---|---|
|
|
||||||||
|
|
||||||||
|
|
||||||||
|
|
リンク無しの社名は OpenBizGraph 未登録企業
§05
関連図
資本関係
得意先
仕入先
業務提携
銀行・株主
ドラッグで移動 · クリックで詳細へ
§06
沿革
The Origins of Cellular Reprogramming
Established in 2003 by preeminent Japanese university researchers, REPROCELL quickly became the leading stem cell research company in Japan.
REPROCELL was listed on the Japan JASDAQ / Growth stock market.
16 July 2026
§07
ニュース
ニュースはありません。
§09
出典・更新
DOMAIN単独ドメイン：あり
UPDATED2026-10-02 19:07 · Model: gpt-4.1-nano